METASTATIC INVASIVE BREAST CANCER
Clinical trials for METASTATIC INVASIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC INVASIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for METASTATIC INVASIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a drug that blocks HER proteins re-sensitize resistant breast cancer to hormone therapy?
Disease control Not yet recruitingThis trial investigates whether adding neratinib, a drug that blocks HER2/3/4 proteins, to standard hormone therapy can improve disease control in people with metastatic ER+/HER2- breast cancer that has stopped responding to first-line endocrine therapy. Participants will receive…
Matched conditions: METASTATIC INVASIVE BREAST CANCER
Phase: PHASE2 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Blood test could signal when to switch breast cancer therapy before tumors grow
Disease control Not yet recruitingThis phase 3 trial tests whether monitoring tumor DNA in the blood (ctDNA) can help doctors switch hormone therapy earlier in people with ER+/HER2- metastatic breast cancer. Participants whose ctDNA levels rise—before any symptoms or scans show progression—are randomly assigned t…
Matched conditions: METASTATIC INVASIVE BREAST CANCER
Phase: PHASE3 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC